-
New
- COVID-19: IP Chronicle
-
COVID-19 posted long-lasting influence on the IP industry around the world, China IP collates recent COVID-19 information related to intellectual property rights for you.
-
New
- Wang Chuang: Institutional Innovation and Development of Judgment Rules of the Supreme People's Court
-
Vice President of the Intellectual Property Court of the Supreme People's Court, Wang Chuang, delivered a keynote speech on the theme of Institutional Innovation and Development of Adjudication Rules
-
New
- CNIPA Statistics on Patents, Trademarks, Geographical Indications, etc. from January to May 2020
-
According to China Intellectual Property Administration (CNIPA) main statistics on intellectual property, from January to May 2020, are shown as follow.
-
New
- Summary of the Judgments of the Intellectual Property Court of the Supreme People's Court (2019)
-
Thirty-six typical cases were selected, reflecting the judicial philosophy, trial ideas and adjudication methods of the Supreme People's Court Intellectual Property Court
-
New
- Top 10 IPR Cases of Internet and Software Industry in 2019
-
China IP planned and launched the selection and voting activities of the “2019 Top Ten Intellectual Property Cases of the Internet and Software Industry”.
-
New
- IP: Building an Innovative and Inclusive Future for Business
-
-- The 9th BIP Asia Forum held in Hong Kong
-
New
- China's Intellectual Property System and Development Trends in 2020
-
About the Authors: Department of Law and Intellectual Property, University of Chinese Academy of Sciences
-
New
- Started with Publicity Week, Ended with Patent Week
-
The 2019 鈥淚ntellectual Property Service Long March鈥� Ended Successfully in Hubei
-
New
- Remarkable Results in the Facilitation of Trademark Registration
-
The number of trademark applications in China has increased rapidly, which result in large demand for trademark registration and the change of registration.
-
New
- Can Me-Too Drugs Be Marketed during Patent Valid Period?
-
In current practice, whether an act of administrative approval can be accommodated under Bolar exemption, has not been generally agreed upon among National Medical Products Administration (NMPA).
